Market Overview

UPDATE: Credit Suisse Initiates Pharmacyclics at Outperform on Pure Play Potential

Related PCYC
Credit Suisse Raises Q2 Imbruvica Sales Forecast For Pharmacyclics
Pharmacyclics' Imbruvica Under FDA Priority Review - Analyst Blog

Credit Suisse initiated coverage on Pharmacyclics, Inc. (NASDAQ: PCYC) with an Outperform rating and a $79.00 price target.

Credit Suisse noted, "We believe that PCYC is the most derisked and investible pure play in the emerging oral lymphoma/leukemia drug class with blockbuster potential. The biggest remaining question is how large the could market be. We believe that experience with Revlimid and Gleevec provide strong evidence that worldwide markets likely exceed $5B, and ibrutinib is positioned to be both first-in-class and best-in-class in key market segments."

Pharmacyclics closed at $65.15 on Monday.

Posted-In: Credit SuisseAnalyst Color Initiation Pre-Market Outlook Analyst Ratings

 

Most Popular

Related Articles (PCYC)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free